ASCO 2020：11项华北地区研究入选口头报告，17项Poster报告

受全球新冠疫情影响，原定于5月29日~6月2日在芝加哥召开的美国临床该学会（ASCO）筹备会议明年将首次以直通上形式召开，这是目前最大规模的直通上盛会。现在，内阁会议的简短题目公布，共103个sessions，当中国总计11项数据比对崭露头角口头报告，17项崭露头角Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他滨常用HER2+移转到特质乳腺肿瘤（PHOEBE）：一项III期随机检验。

三场：移转到特质乳腺肿瘤

编者：当中国医学科学院的医院徐兵河讲师、马飞讲师，复旦大学附属的医院胡夕春讲师等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴特质乳腺肿瘤标准疗法后卡培他滨维持节拍疗法的III期检验（SYSUCC-001）。

三场：乳腺肿瘤—发散/区域/常规疗法

编者：当永安大学传染病当中心王树森讲师等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移转到特质脑的表型特征来预测脑脊液当中周而复始DNA检测的概率: 新机器对抗杨家竞争对手

三场：新机器解决杨家原因

编者：李美芹 李德兰等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

利诺非尼对比索拉非尼作为更早肝蛋白质肿瘤的一直通疗法：一项封闭关键字、随机、多当中心II/III期检验。

三场：食道肠道肿瘤—食道胃、发挥作用和实乃

编者：四川大学华西的医院毕锋讲师、当中国民众解放军海军八一的医院秦叔逵讲师等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

当中国更早肝肿瘤病征阿帕替尼二直通疗法：一项随机、安慰剂相异、双盲III期数据比对

三场：食道肠道肿瘤—食道胃、发挥作用和实乃

编者：当中国民众解放军海军八一的医院秦叔逵讲师、四川大学华西的医院李秋讲师等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

更早患特质卵巢肿瘤二次蛋白质减灭术的一项随机III期检验：SOC1 / SGOG-OV2。

时事：妇科肿瘤症

编者：复旦大学附属当永安的医院臧荣余讲师等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治特质子宫切除术后常规疗法当中的序贯放疗法对比单独MRI或同步放疗法（STARS数据比对）：一项随机、相异、封闭关键字的III期检验。

内阁会议：妇科肿瘤症

编者：当永安大学传染病当中心大白讲师、刘继红讲师等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比疗法常用可切除的EGFR突变的N1-N2期NSCLC-随机III期临床检验的最终总体共存比对。

时事：肝肿瘤—非小蛋白质发散-区域/小蛋白质/其他胸部

编者：广东省民众的医院吴一龙讲师等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡移转到非小蛋白质肝肿瘤病征一直通乙酰激酶抑制建立联系或不建立联系全力前直通发散MRI：III期封闭关键字临床随机检验（SINDAS）的当中期结果（NCT02893332）。

时事：肝肿瘤-非小蛋白质移转到

编者：四川省民众的医院曾铭讲师等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序特质生还-1（PD-1）的人源化IgG4单克隆抗体建立联系阿昔替尼常用移转到特质表皮乳肿瘤病征的Ib期数据比对的总共存期和生物圣万比对。

时事：乳肿瘤/皮肤肿瘤

编者：北京大学的医院郭军、盛锡楠讲师等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全特质和结果：非标准CAR-T蛋白质首次人体检验疗法患/难治特质T蛋白质急特质淋巴蛋白质前列腺癌（r/r T-ALL）的安全特质和。内阁会议：开发当中的疗法新科技-免疫疗法。编者：王欣欣等简短：3013月历：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利类药物在更早胃突起蛋白质肿瘤病征当中的分析方法：一项随机的封闭关键字II期检验（ORIENT-2）。内阁会议：食道肠道肿瘤-食道胃肿瘤、发挥作用肿瘤和实乃道肿瘤编者：徐建明讲师等简短：4511月历：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异特质CAR-T蛋白质对髓母蛋白质瘤的根除特质疗法内阁会议：当神经系统编者：代红久、孙斌、杨东、徐晖、陈美美、魏佳、赵旭东简短：2522月历。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在更早错配修复原因病征当中的分析方法内阁会议：开发当中的疗法学-免疫疗法编者：沈琳讲师等简短：3021月历。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 内皮CD7-CART疗法患/难治特质ACUTE淋巴蛋白质前列腺癌/淋巴瘤的首例人体临床检验内阁会议: 开发特质疗法学-免疫疗法编者简介：张明志，白水等简短：3026月历: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 西米替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）建立联系应常用更早实体瘤病征的Ib期数据比对内阁会议：发展特质疗法学；还有分子靶向制剂和生物学编者：龚继芳，沈琳讲师等简短：3523月历：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin建立联系紫杉醇和nedaplatin疗法患特质或移转到特质胃突起蛋白质肿瘤（ESCC）病征的II期数据比对。内阁会议：食道肠道肿瘤-食道胃、发挥作用和实乃道肿瘤的数据比对编者：王志最弱，李玉红，王德申，王凤华，任超，谭琼 王志最弱、李玉红、王德深、王凤华、任超、谭琼简短：4522月历：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.内阁会议：食道肠道肿瘤-食道胃肿瘤、发挥作用肿瘤和实乃管肿瘤的二直通疗法编者：宋艳等简短：4524月历：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种肾脏外体网状RNA线性常用初始活检时检测高等级肿瘤的肾脏外体网状RNA线性：一项多当中心的回顾特质数据比对内阁会议：泌尿睾丸肿瘤症；还有-肿瘤、睾丸肿瘤和肿瘤编者简介：Liaoyuan Li等简短：5522月历。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 发散更早宫颈肿瘤即刻疗法后的常规疗法内阁会议: 妇科肿瘤症编者简介： 李珉珉等简短：6031月历：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法甲状腺髓特质肿瘤的相关特质：基于ALTER01031检验的比对。会话：头颈部编者：天津市的医院高明讲师简短：6526月历。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、尺寸和成年人对安洛替尼疗法后病征结局的影响: ALTER01031的亚组比对内阁会议：头颈部编者：天津市的医院高明讲师简短：6527月历。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA比对预测I-IIIA期非小蛋白质肝肿瘤（NSCLC）病征术后患: GASTO1035和GASTO1018的结果内阁会议：肝肿瘤-非小蛋白质发散-区域特质/小蛋白质/小蛋白质/其他胸科肿瘤症编者：Si-Yu Wang等简短：9023月历：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质肝肿瘤（NSCLC）当中EGFR乙酰激酶抑制的新型致病组态内阁会议:肝肿瘤-非小蛋白质移转到特质肝肿瘤编者简介：赵昕，金玲玲，满宇，欧秋香，和黄，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、和黄、薛武、杨绍、范敏简短：9528月历：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1检验当中更早乳肿瘤总共存的替代终点内阁会议：乳肿瘤/皮肤肿瘤编者：聂润聪，袁书最弱，李元芳，陈英波，周志伟 聂润聪、袁书最弱、李元芳、陈英波、周志伟简短：10030月历：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法患或移转到特质原发特质恶特质骨病征的II期数据比对内阁会议： 畸形编者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、英宗、蔡启庆、涂崇奇、范正福、杨瑶简短：11525月历。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步称赞安罗替尼在更早畸形病征多直通疗法当中的安全特质和。内阁会议：畸形编者：姚伟涛，王家最弱，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家最弱、张鹏、王鑫、杜鑫辉、田志超、牛晓英简短：11526月历：414